Clinical Trials · NCT03574597
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 17,604
- Start date
- Oct 2018
- Locations
- 833 sites, 42 countries
- Primary endpoint
- Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke